GlaxoSmithKline

The momentum for this stock is not very good. GlaxoSmithKline has good value characteristics. The stock will provide you with a reasonable dividend income. GlaxoSmithKline is not very popular among insiders. GlaxoSmithKline is a mediocre stock to choose.

GlaxoSmithKline Plc is a global healthcare company which engages in researching, developing and manu...

News

GSK Reveals 'Positive' Data From Mid-Stage Study Of Seasonal Influenza mRNA Vaccine

Benzinga GSK announced positive phase 2 trial results for its mRNA seasonal flu vaccine, showing strong immune.\n more…

GSK Executives Invest in Company Shares

TipRanks Financial Blog GlaxoSmithKline (GB:GSK) has released an update. Key executives at GlaxoSmithKline, including CEO Emma Walmsley and CFO Julie Brown, have recently acquired Ordinary...\n more…

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

Zacks Investment Research It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different...\n more…

GSK, CureVac mRNA flu shot reaches late-stage studies

SeekingAlpha.com: All News GSK (GSK) advances its messenger-RNA-based flu vaccine candidate developed with CureVac (CVAC) into late-stage development after positive mid-stage data. Read more here.\n more…

Fulcrum crashes as GSK-partnered lead program fails

Seeking Alpha - Healthcare Fulcrum crashes as GSK-partnered lead program fails...\n more…

PFG Investments LLC Increases Stock Holdings in GSK plc (NYSE:GSK)

Ticker Report PFG Investments LLC boosted its position in shares of GSK plc (NYSE:GSK - Free Report) by 3.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and...\n more…